Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) From Asofarma de México S.A. de C.V. vs. JARDIANCE® (25 mg Tablets) From Boehringer Ingelheim Pharmaceuticals Inc., in Healthy Research Subjects, Under Fasting Conditions

NCT07479108 is registered in ClinicalTrials.gov with ADIUM as lead sponsor.

NCT NCT07479108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07479108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) From Asofarma de México S.A. de C.V. vs. JARDIANCE® (25 mg Tablets) From Boehringer Ingelheim Pharmaceuticals Inc., in Healthy Research Subjects, Under Fasting Conditions
Lead sponsor
ADIUM
Phase
Not applicable
Overall status
Completed
Start date
November 29, 2024
Completion date
December 11, 2024
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalance